Do we need Better Strategies to Prevent Osteoporotic Fractures?

Save

In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.

FDA Delays Gout Drug NASP with Complete Response Letter

Save

At the end of June, Sobi was awaiting an FDA decision on its Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled gout. On June 26, 2026, SOBI received a Complete Response Letter from the U.S. FDA that will delay a decision on NASP, pending the company's answer to questions regarding the drugs manufacturing at a 3rd party facility in China.

NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan

Save

The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic

DMARD Efficacy in RA-ILD

Save

A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional, low-certainty recommendations.

The Power of Self-Management with Chronic Low Back Pain

Save

Almost everyone will deal with back pain at some point in their lives.

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Save

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.

EULAR26: ANCHOR-RA Study of RA-ILD

Save

People with rheumatoid arthritis are at risk of developing interstitial lung disease (RA-ILD), which is associated with high mortality.

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

Save

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

EULAR26: GLP-1 Agonist Use in the RISE Registry

Save

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

ICYMI: Glucocorticoid Injections in Knee Osteoarthritis

Save

A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).

ICYMI: EGPA Review

Save

A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.

Spotlight on Comorbidities from EULAR 2026

Save

Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the risk of

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Save

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

ICYMI: B Cells at the Brink in Sjögren Disease

Save

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

EULAR26: Reports on Systemic Sclerosis

Save

In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (mDAI) score of less than 2.5 at baseline (inactive), versus those with 2.5 or higher (active).

Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd